• Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Unspecified (DepMap=ACH-001354).
  

PubMed=856461
Seeger R.C., Rayner S.A., Banerjee A., Chung H., Laug W.E., Neustein H.B., Benedict W.F.
Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines.
Cancer Res. 37:1364-1371(1977)

PubMed=7037175
Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.
Selective toxicity of 6-hydroxydopamine and ascorbate for human neuroblastoma in vitro: a model for clearing marrow prior to autologous transplant.
Cancer Res. 42:1331-1336(1982)

DOI=10.1016/B978-0-12-008304-6.50015-4
Biedler J.L., Meyers M.B., Spengler B.A.
Homogeneously staining regions and double minute chromosomes, prevalent cytogenetic abnormalities of human neuroblastoma cells.
(In book chapter) Advances in cellular neurobiology, Vol. 4; Fedoroff S., Hertz L. (eds.); pp.267-307; Academic Press; New York; USA (1983)

DOI=10.1007/0-306-46872-7_2
Thiele C.J.
Neuroblastoma.
(In book chapter) Human cell culture. Vol. 1. Cancer cell lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York; USA (1999)

PubMed=15720811; DOI=10.1593/neo.04310; PMCID=PMC1531688
Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F., Biedler J.L., Cheung N.-K.V., Ross R.A.
Characteristics of stem cells from human neuroblastoma cell lines and in tumors.
Neoplasia 6:838-845(2004)

PubMed=18923524; DOI=10.1038/nature07399
Chen Y.-Y., Takita J., Choi Y.L., Kato M., Ohira M., Sanada M., Wang L.-L., Soda M., Kikuchi A., Igarashi T., Nakagawara A., Hayashi Y., Mano H., Ogawa S.
Oncogenic mutations of ALK kinase in neuroblastoma.
Nature 455:971-974(2008)

PubMed=24466371; DOI=10.1593/tlo.13544; PMCID=PMC3890703
Loschmann N., Michaelis M., Rothweiler F., Zehner R., Cinatl J., Voges Y., Sharifi M., Riecken K., Meyer J., von Deimling A., Fichtner I., Ghafourian T., Westermann F., Cinatl J. Jr.
Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs.
Transl. Oncol. 6:685-696(2013)